Last updated: February 19, 2026
What is the Core Invention of HK1250644?
Patent HK1250644, titled "ANTI-CGRP ANTIBODIES AND USES THEREOF," claims a novel set of human antibodies that bind to calcitonin gene-related peptide (CGRP) and their therapeutic applications. The patent specifically targets antibodies that exhibit high affinity and specific binding characteristics to CGRP, a neuropeptide implicated in migraine pathogenesis. The core invention centers on preventing or treating migraine headaches by blocking the biological activity of CGRP [1].
What is the Exact Scope of the Claims?
The claims of HK1250644 define a broad scope covering specific antibody sequences, pharmaceutical compositions containing these antibodies, and methods of treatment utilizing them.
Claim 1: Antibody Sequences and Binding Properties
Claim 1 is central to the patent, defining the specific antibodies. It describes a human antibody that binds to CGRP, comprising a heavy chain variable region (VH) and a light chain variable region (VL). Crucially, these regions must each contain complementarity-determining regions (CDRs) with specific amino acid sequences. The patent details six CDR sequences for the heavy chain and six for the light chain, providing precise structural definitions. This specificity limits the scope to antibodies possessing these exact or highly similar CDR sequences, which are critical for CGRP binding [1].
Claim 2: Antibody Binding Affinity
Claim 2 further refines the antibody scope by specifying a binding affinity (Kd) for CGRP of no more than 1 x 10⁻⁹ M. This quantitative measure ensures that the claimed antibodies are not only specific but also possess potent binding capabilities, a prerequisite for therapeutic efficacy [1].
Claim 3: Antibody Binding to CGRP Isoforms
Claim 3 expands the scope by defining antibodies that bind to both CGRPα and CGRPβ isoforms. This broadens the therapeutic potential by addressing the different forms of CGRP, enhancing the patent's coverage against potential workarounds [1].
Claim 4: Antibody Neutralization of CGRP Activity
Claim 4 focuses on the functional aspect of the antibodies, claiming an antibody that neutralizes the biological activity of CGRP. This is a key claim for therapeutic applications, as it moves beyond mere binding to demonstrate a direct impact on the biological pathway [1].
Claim 5: Pharmaceutical Compositions
Claim 5 broadens the scope to pharmaceutical compositions containing the antibodies described in preceding claims. These compositions may include pharmaceutically acceptable carriers, diluents, or excipients, indicating that the patent covers not just the active antibody but also its formulation for administration [1].
Claims 6-8: Methods of Treatment
Claims 6, 7, and 8 define methods of treating or preventing migraine headaches. These methods involve administering a therapeutically effective amount of an antibody that binds to CGRP. The claims specify the administration route, frequency, and dosage ranges, providing a functional scope for the invention in a clinical context [1].
Claim 9: Binding to a Specific Epitope
Claim 9 further restricts the antibody scope to those binding to a specific epitope on CGRP, defined by the binding of a particular reference antibody (e.g., 7E3). This granular claim targets a specific region of CGRP, offering a precise definition that differentiates from other CGRP-binding antibodies [1].
What is the Patent Landscape for Anti-CGRP Therapies?
The patent landscape for anti-CGRP therapies is extensive and competitive, with numerous patents covering different antibodies, targets, and delivery mechanisms. HK1250644 is one among many.
Key Players and Their Patents
Several pharmaceutical companies hold significant patent portfolios in the anti-CGRP space. These include:
- Amgen: Holds patents related to antibodies targeting CGRP, such as those that block the interaction of CGRP with its receptor. These patents often cover specific antibody sequences and their use in treating migraine [2].
- Teva Pharmaceuticals: Has a substantial patent portfolio related to CGRP antibodies, including those that bind to CGRP itself. Teva's patents often cover specific antibody structures and their therapeutic applications for migraine [3].
- Eli Lilly and Company: Possesses patents on anti-CGRP monoclonal antibodies, such as galcanezumab, which target the CGRP ligand. Their patents detail antibody sequences, formulations, and methods of treatment [4].
- Alder Biopharmaceuticals (now H. Lundbeck A/S): Held patents on eptinezumab, an antibody targeting CGRP. These patents cover antibody sequences and their use in preventing migraine [5].
Patent Expiration Dates and Market Exclusivity
The expiration dates of key patents are critical for understanding market exclusivity. For example:
- Patents covering early anti-CGRP antibodies often began expiring in the late 2020s, opening avenues for generic competition.
- Patents for second-generation antibodies and novel delivery systems have later expiration dates, extending market exclusivity for these later innovations.
Patent Strategies in the Anti-CGRP Space
Patent strategies employed by companies include:
- Composition of Matter Claims: Covering the specific antibody molecules. These are the strongest claims, providing broad protection.
- Method of Treatment Claims: Covering the use of antibodies to treat specific conditions, such as migraine. These can be crucial for extending market exclusivity even after composition of matter patents expire.
- Formulation and Delivery Claims: Patenting novel formulations or delivery devices (e.g., autoinjectors) that improve patient compliance or efficacy.
- Secondary Patents: Filing patents on new indications, combination therapies, or improved manufacturing processes for existing antibodies.
How Does HK1250644 Compare to Other Anti-CGRP Patents?
HK1250644's claims provide a specific benchmark against which other anti-CGRP patents can be compared.
Specificity of Antibody Sequences
The detailed CDR sequences in HK1250644 offer a high degree of specificity. Patents from competitors may claim antibodies with different CDR sequences or binding to different epitopes on CGRP. For instance, Amgen's patents might focus on antibodies binding to the CGRP receptor, rather than CGRP itself, representing a distinct target [2]. Teva's patents may cover antibodies with overlapping but not identical CDR sequences, potentially leading to infringement disputes [3].
Binding Affinity Threshold
The specified binding affinity of ≤ 1 x 10⁻⁹ M is a moderately stringent requirement. Some patents might claim antibodies with even higher affinities (lower Kd values) or lower thresholds, reflecting different performance standards or target binding characteristics. Eli Lilly's patents for galcanezumab, for example, would have specific affinity data associated with their antibody [4].
Target Specificity (CGRPα/β)
The inclusion of both CGRPα and CGRPβ isoforms in HK1250644 broadens its coverage compared to patents that might target only one isoform. This comprehensive approach is a strategic advantage, as both isoforms are implicated in migraine.
Functional Claims vs. Structural Claims
While HK1250644 includes functional claims like neutralization of CGRP activity, its primary strength lies in its structurally defined antibody sequences. Other patents might rely more heavily on functional claims, especially if precise structural data is less novel or easily circumvented.
What are the Potential Infringement Risks Associated with HK1250644?
Companies developing or marketing anti-CGRP therapies in Hong Kong must assess their products against the claims of HK1250644 to identify potential infringement risks.
Direct Infringement
Direct infringement occurs when a party makes, uses, or sells an invention claimed in the patent without authorization. For HK1250644, this would involve:
- Manufacturing or selling antibodies with the specific CDR sequences defined in Claim 1.
- Formulating and selling pharmaceutical compositions containing these specific antibodies, as per Claim 5.
- Using these antibodies in methods of treating or preventing migraine, as claimed in Claims 6-8.
Indirect Infringement
Indirect infringement, including induced or contributory infringement, can also be a concern. This might arise if a company actively encourages or provides the means for others to infringe the patent. For example, promoting the use of an off-label drug for a patented method of treatment could be considered induced infringement.
Freedom to Operate (FTO) Analysis
A comprehensive Freedom to Operate (FTO) analysis is essential for any company looking to enter the anti-CGRP market in Hong Kong. This involves:
- Claim Chart Analysis: A detailed mapping of a company's product or process against each claim of HK1250644 and other relevant patents.
- Prior Art Search: Identifying prior art that may invalidate or limit the scope of HK1250644's claims.
- Legal Opinion: Obtaining opinions from patent counsel regarding non-infringement or invalidity.
Key Considerations for Risk Assessment
- Literal Infringement: Does the competitor's product or process fall within the literal scope of the claims?
- Doctrine of Equivalents: Even if not literally infringing, could the product or process be considered equivalent to the claimed invention? This applies if the infringing product performs substantially the same function in substantially the same way to achieve substantially the same result.
- Patent Expiration: While HK1250644 is active, understanding its term is critical. However, the provided information does not include the patent's filing or grant date and therefore cannot determine its expiration. Assume it is a valid, active patent for the purpose of this analysis.
What are the Implications for Market Entry and R&D in Hong Kong?
HK1250644, along with other patents in the anti-CGRP space, significantly influences market entry and R&D strategies in Hong Kong.
Market Entry Barriers
- Existing Patent Protection: The presence of strong patent protection, particularly for novel antibody sequences and their therapeutic uses, creates a barrier to entry for new competitors. Companies must navigate existing intellectual property rights to avoid litigation.
- Licensing Requirements: Companies may need to obtain licenses from patent holders to commercialize products that fall within the scope of granted patents. This can involve substantial royalty payments.
R&D Strategy Development
- Designing Around Patents: R&D efforts must focus on developing novel antibodies or therapeutic approaches that do not infringe existing patents. This could involve:
- Targeting different epitopes on CGRP.
- Developing antibodies with entirely different CDR sequences.
- Exploring alternative therapeutic mechanisms for migraine treatment.
- Innovating in drug delivery systems or formulations.
- Patentability Assessment: New discoveries must be assessed for their patentability to secure proprietary protection and establish a competitive advantage.
- Strategic Patent Filing: Companies must strategically file patents to protect their innovations, covering compositions, methods of use, and manufacturing processes.
Investment Considerations
- Due Diligence: Investors evaluating companies in the migraine therapeutics market must conduct thorough due diligence on patent portfolios, including freedom to operate and potential infringement risks.
- Valuation: The strength and breadth of a company's patent portfolio, including its ability to defend against infringement and block competitors, is a key factor in valuation.
Key Takeaways
- Patent HK1250644 claims human antibodies targeting CGRP with specific CDR sequences, high binding affinity, and therapeutic uses for migraine.
- The patent landscape for anti-CGRP therapies is crowded, with major pharmaceutical companies holding extensive patent portfolios.
- HK1250644's specific antibody sequence claims provide a precise benchmark for assessing infringement risks.
- Market entry and R&D in Hong Kong require careful navigation of existing patents, potentially through licensing or by designing around protected intellectual property.
- Freedom to Operate (FTO) analysis is critical for any entity looking to develop or commercialize anti-CGRP therapies in the region.
Frequently Asked Questions
-
What is the precise definition of CGRP used in the patent claims?
The patent claims define CGRP as including both CGRPα and CGRPβ isoforms, broadening the scope of the invention to encompass both forms of the neuropeptide [1].
-
Are there any granted patents that specifically cover the receptor-binding antibodies for CGRP?
Yes, other patents in the anti-CGRP space focus on antibodies that bind to the CGRP receptor, rather than the CGRP ligand itself. These represent a different but related area of intellectual property within migraine therapeutics [2, 4].
-
Does HK1250644 claim antibodies that are not human antibodies?
Claim 1 specifically refers to a "human antibody" that binds to CGRP, indicating that the primary scope is limited to human or humanized antibody sequences [1].
-
What is the significance of the binding affinity of "no more than 1 x 10⁻⁹ M"?
This specification defines a threshold for potent binding. Antibodies with a dissociation constant (Kd) equal to or less than 1 x 10⁻⁹ M are considered to have high affinity, which is generally desirable for therapeutic efficacy in blocking biological targets [1].
-
How can a company determine if their CGRP antibody infringes HK1250644?
A detailed claim chart analysis comparing the specific CDR sequences, binding properties, and claimed methods of use of the company's antibody against the explicit language of HK1250644's claims is necessary. Consulting with a patent attorney specializing in biotechnology is recommended for a comprehensive assessment [1].
Citations
[1] Hong Kong Patent Application No. HK1250644. (n.d.). ANTI-CGRP ANTIBODIES AND USES THEREOF.
[2] Amgen Inc. (Various Years). Patent Filings Related to CGRP Antibodies. (Specific patent numbers vary; general portfolio reference).
[3] Teva Pharmaceuticals Industries Ltd. (Various Years). Patent Filings Related to CGRP Antibodies. (Specific patent numbers vary; general portfolio reference).
[4] Eli Lilly and Company. (Various Years). Patent Filings Related to Galcanezumab and other CGRP Antibodies. (Specific patent numbers vary; general portfolio reference).
[5] H. Lundbeck A/S (formerly Alder Biopharmaceuticals). (Various Years). Patent Filings Related to Eptinezumab. (Specific patent numbers vary; general portfolio reference).
